Introduction
The process of malignant transformation is almost invariably associated with a heightened cell survival threshold (Luo et al., 2009) , which in turn contributes to disease progression, metastatic dissemination and resistance to conventional or targeted therapy. Defying cell death under these conditions typically involves aberrant expression and function of antiapoptotic mechanisms coordinated by Bcl-2 or inhibitor of apoptosis (IAP) gene families, which oppose mitochondrial dysfunction (Cory and Adams, 2002) or antagonize caspase activity (Srinivasula and Ashwell, 2008) , respectively. Conversely, intrinsic pro-cell-death signals can be activated to oppose these cytoprotective processes by silencing the expression of survival factors (Accili and Arden, 2004) , antagonizing their functions (Du et al., 2000) or upregulating the cellular levels of death effectors (Vogelstein et al., 2000) .
Such endogenous cell death pathways are likely to have an important role against malignant transformation, as multiple tumor suppression mechanisms overlap in their ability to remove a cell survival advantage and execute apoptosis (Lowe et al., 2004) . One of the targets of disparate tumor suppression networks is survivin (Altieri, 2008) , a unique IAP protein with essential roles in the control of mitosis and protection from apoptosis, whose expression in cancer is required to maintain the malignant phenotype. In this context, strategies to mimic or (re)activate an endogenous cell death machinery are being intensely pursued for novel cancer therapeutics (Fesik, 2005) , and targeting survivin may provide an attractive approach to lower a global antiapoptotic and proliferative threshold in tumor cells (Mita et al., 2008) .
Caspases are pivotal effectors of the intrinsic cell death machinery. This has been historically linked to their ability to dismantle the cellular architecture (Shi, 2002) , but many of these molecules have been recently found intercalated in multiple signaling mechanisms of cell proliferation, migration and differentiation (Li and Yuan, 2008 ) that may also contribute to cell death regulation. There is correlative evidence that, at least in some cases, caspase signaling in cell proliferation may antagonize tumor growth in vivo. Accordingly, loss or inactivation of caspase 3 (Soung et al., 2004) , caspase 10 (Shin et al., 2002) or caspase 8 (Stupack et al., 2006) has been documented in several types of human tumors and potentially associated with disease dissemination and unfavorable outcome. In this context, caspase 2 is an evolutionarily conserved apical caspase (Krumschnabel et al., 2009) , whose pleiotropic signaling properties have been associated with endoplasmic reticulum stress (Upton et al., 2008) , cytoskeletal disruption (Ho et al., 2008) , mitotic catastrophe (Castedo et al., 2004) , p53dependent DNA damage (Baptiste-Okoh et al., 2008) and, more recently, tumor suppression in vivo (Ho et al., 2009) . Although caspase 2 knockout mice show no overt phenotype (Bergeron et al., 1998) , caspase 2 À/À fibroblasts are more prone to oncogenic transformation, resist apoptosis and exhibit accelerated tumor growth in mice (Ho et al., 2009 ). However, the mechanistic underpinning of how caspase 2 may function in endogenous tumor suppression has not been elucidated (Ho et al., 2009) .
In this study, we investigated mechanisms of cell death regulation in tumor cells, and we unraveled a novel pathway of caspase 2-mediated tumor suppression centered on acute silencing of the survivin gene.
Results

Caspase 2 activity represses survivin gene expression in tumor cells
We began this study by testing the effect of anticancer agents on caspase activity, and we focused on caspase 2 for its role at the interface between cell proliferation signaling and apoptosis (Troy and Shelanski, 2003) . Treatment of HCT116 colorectal cancer cells with the small molecule heat shock protein-90 inhibitor, 17-allylaminogeldanamycin (17-AAG) or the DNAdamaging agent, cisplatin (CDDP), resulted in concentration-dependent increase in caspase 2 activity (Figure 1a ). To test the specificity of this response, we next treated breast adenocarcinoma MCF-7 cells as well as HCT116 cells with the chemotherapeutic agent, taxol, and monitored caspase 2 activity side-by-side with cleavage of caspase 3. Taxol treatment induced robust and timedependent increase in caspase 2 activity ( Figure 1b ). However, this was not associated with detectable caspase 3 proteolytic activation (Figure 1c ), indicating that caspase 2 activity was specific for this caspase. Conversely, proteolytic cleavage of caspase 3 was detectable at high concentrations of CDDP ( Figure 1c ) and 17-AAG (data not shown). To test whether a potential caspase 2 response affected cell survival pathways, we next transfected HCT116 cells with a caspase 2 cDNA and looked at a potential modulation of IAP proteins (Srinivasula and Ashwell, 2008) . In these experiments, transfection of caspase 2 in HCT116 cells did not significantly reduce cell viability (see below). Conversely, caspase 2-expressing cells exhibited concentration-dependent loss of endogenous survivin levels (Figure 1d ), whereas a related IAP, XIAP (Srinivasula and Ashwell, 2008) , was not affected (see below).
To determine whether caspase 2 modulation of survivin occurred at the level of gene transcription, we next transfected HCT116 cells with the proximal 830 nt of the mouse survivin promoter fused to a green fluorescent protein (GFP) reporter gene (ms-830-GFP) (Xia and Altieri, 2006) . In the presence of a control plasmid or no plasmid, transfected cells expressed GFP under the control of the survivin promoter, as shown by fluorescence microscopy (Figure 1e ). In contrast, transfection of caspase 2 nearly completely abolished the GFP þ population of HCT116 cells (Figures 1e and f ), suggesting that transcription of the survivin gene was repressed under these conditions. Similar results were obtained in p53 þ / þ or p53 À/À HCT116 cells (Figure 1f ), showing that p53 was not involved in survivin gene modulation by caspase 2 (Hoffman et al., 2002; Mirza et al., 2002) . Consistent with this model, transfection of caspase 2 in HCT116 cells suppressed transcription of several human survivin promoter constructs extending up to À1430 nt from the transcription start site(s), as shown by luciferase reporter assay (Figure 1g ). This response was specific for caspase 2, as expression of caspase 3 had no effect on survivin gene expression in p53 þ / þ or p53 À/À HCT116 cells (Figure 1h ).
Caspase 2 targeting modulates endogenous survivin expression in tumor cells
In complementary experiments, we next acutely silenced caspase 2 expression in HCT116 cells using small interfering RNA (siRNA) and looked at potential changes in endogenous survivin levels. Caspase 2directed siRNA efficiently suppressed caspase 2 protein levels in HCT116 cells as compared with control siRNA (Figure 2a ), and this resulted in upregulation of endogenous survivin expression, as shown by western blotting (Figure 2a ), and semi-quantitative and quantitative PCR (Figure 2b ). Conversely, caspase 2 silencing had no effect on XIAP expression in HCT116 cells (Figure 2a ). As control, acute knockdown of endogenous caspase 3 ( Figure 2c ) or caspase 8 ( Figure 2d ) did not modulate survivin levels in HCT116 cells as compared to a non-targeted siRNA, thus confirming the specificity of the caspase 2 response (Figures 2c and d ).
Requirement of caspase 2 catalytic activity for modulation of survivin gene expression
Forced expression of caspase 2 in cells has been associated with the generation of an active enzyme, potentially by autoproteolytic processing (Troy and Shelanski, 2003) or induced proximity (Bouchier-Hayes et al., 2009) . To formally test whether the enzymatic activity of caspase 2 was required for survivin gene regulation, we next generated caspase 2 variants lacking the prodomain, thus mimicking a constitutively active enzyme (Casp.2 152 Ac) (Li et al., 1997) , or carrying an Ala substitution of the active site Cys320 (C320A), which produces a catalytically dead enzyme ( Figure 3a ). Consistent with these predictions, p53 þ / þ or p53 À/À HCT116 cells transfected with full-length caspase 2 exhibited a twofold increase in the enzymatic activity, whereas prodomain-deleted caspase 2 was considerably more active and a C320A caspase 2 mutant had no activity ( Figure 3b ). Under these conditions, wild-type (WT) caspase 2 or constitutively active caspase 2 suppressed survivin promoter-directed GFP expression in HCT116 cells, as shown by fluorescence microscopy (Figures 3c and d) , and western blotting ( Figure 3e ). In contrast, active site-mutant caspase 2 did not affect survivin promoter activity in HCT116 cells ( Figures  3c-e ). Confirming the specificity of this response, transfection of HCT116 cells with active caspase 2 did not affect the expression of an unrelated plasmid, that is, pEGFP (Figure 3f ). Altogether, these data indicate that the catalytic activity of caspase 2 is required to suppress survivin gene transcription.
Mitotic defects and apoptosis induced by caspase 2 silencing of survivin
To investigate the consequence(s) of caspase 2 downregulation of survivin, we next generated clones of HCT116 cells that stably express caspase 2 or control plasmid. Generation of stable caspase 2 transfectants was feasible ( Figure 4a ) and resulted in significant repression of survivin gene transcription, as shown by fluorescence microscopy of ms-830-GFP expression ( Figure 4b ) and by luciferase reporter assay ( Figure 4c ). Cell cycle-synchronized HCT116 cells transfected with control plasmid exhibited a periodic increase in survivin expression coinciding with entry into the G2/M-phase of the cell cycle 8 h after thymidine release and persisting throughout the completion of mitosis, 10-12 h after release (Figure 4d ), in agreement with previous observations (Altieri, 2008) . In contrast, HCT116 caspase 2 transfectants showed no increase in survivin expression at mitosis (Figure 4d ). This was associated with slower mitotic transitions, with 21 and 40% of these cells reentering G1-phase at 10 and 12 h after thymidine release, respectively, as opposed to 30 and 51% of control HCT116 cells ( Figure 4e ). Accordingly, caspase 2-expressing cells exhibited persistence of cyclin A expression, as compared with control transfectants (Figure 4d ).
In the absence of cell death stimuli, stable expression of caspase 2 in synchronized HCT116 transfectants did not result in detectable apoptosis at any cell cycle phase tested, as compared with control cultures, by hypodiploid DNA content and flow cytometry ( Figure 4e ) or 4 0 ,6-diamidino-2-phenylindole (DAPI) staining of nuclear apoptosis, as shown by fluorescence microscopy (Figure 5a ). In contrast, exposure of these cells to the cell death stimulus, staurosporine (STS), resulted in increased sensitivity to apoptosis, as compared with control HCT116 transfectants ( Figure 5a ). This cell death response had the hallmarks of apoptosis with increased caspase 3 activity and loss of plasma membrane integrity, as shown by multiparametric flow cytometry of DEVDase activity and propidium iodide staining (Figure 5b ). In addition, knockdown of caspase 2 reversed STS-induced cell death in HCT116 cells, as 
Caspase 2 suppression of tumorigenesis
We next asked whether caspase 2 silencing of survivin affected tumorigenicity. First, HCT116 cells stably expressing caspase 2 exhibited significantly reduced cell proliferation, compared with control transfectants, over a 5-day interval (Figure 6a ). siRNA silencing of caspase 2 in stable HCT116 transfectants ( Figure 6b ) reversed this phenotype and restored cell proliferation to levels comparable or exceeding those of control siRNAtransfected cells (Figure 6c ). Second, expression of caspase 2 in HCT116 cells completely abolished colony formation in soft agar, compared with control transfectants, in a reaction similarly reversed by siRNA silencing of caspase 2, but not control siRNA (Figure 6d ). To further test the specificity of caspase 2 inhibition of tumorigenicity, we next generated stable clones of caspase 2 transfectants in an unrelated tumor cell type, lung cancer H460 cells. Stable expression of caspase 2 in this cell type was also feasible ( Figure 6e ) and, similar to the results with HCT116 cells, was associated with decreased rate of tumor cell proliferation (Figure 6f ). Finally, HCT116 cells stably expressing caspase 2 completely failed to grow as superficial xenograft tumors in immunocompromised mice, whereas control transfectants gave rise to rapidly growing tumors in severe combined immunodeficient (SCID)/beige mice ( Figure 6g ).
Specificity of caspase 2 regulation of survivin expression and tumorigenicity
To validate the specificity of these findings, we next generated stable clones of HCT116 cells that expressed comparable levels of caspase 9 (Figure 7a ), another long prodomain-containing apical caspase (Shi, 2002) , which can also be activated by induced proximity and overexpression in cells. In sharp contrast with caspase 2, HCT116 caspase 9 transfectants exhibited no modulation of endogenous survivin expression, as shown by western blotting (Figure 7a ), and no reduction in survivin promoter-dependent GFP expression, as shown by fluorescence analysis of ms-830-GFP (Figure 7b ), or survivin promoter luciferase activity (Figure 7c ). Functionally, caspase 9-expressing HCT116 cells exhibited kinetics of cell proliferation indistinguishable from those of pcDNA transfectants (Figure 7d ), and formed extensive colonies in soft agar (Figure 7f ). For comparison, another independently established clone of HCT116 cells stably expressing caspase 2 exhibited Caspase 2 targeting of nuclear factor kB activity We next asked whether caspase 2 signaling, particularly by nuclear factor kB (NFkB) regulation (Tinel et al., 2007) , contributed to survivin gene silencing and tumor suppression. First, a radiolabeled DNA probe containing a consensus NFkB site in the proximal survivin promoter, but not a mutant NFkB DNA probe (Figure 8a) , bound nuclear extracts of tumor cells, in a reaction supershifted by an antibody to the p65 subunit of NFkB (Figure 8b ). Accordingly, a WT, but not mutant, unlabeled NFkB consensus sequence inhibited the formation of a survivin promoter-NFkB complex, as shown by electrophoretic mobility shift assay (Figure 8b ).
Next, we mutated one of the NFkB consensus sites in the survivin promoter of ms-830-GFP (Figure 8a) and tested a potential effect on survivin gene expression. Consistent with the data presented above, transfection of these cells with catalytically dead caspase 2 had no effect on GFP expression driven by the WT survivin promoter (Figure 8c ). In contrast, GFP expression was partially reduced in HCT116 cells transfected with the mutant NFkB ms-830-GFP promoter and catalytically dead caspase 2 (Figure 8c ). Altogether, these data suggest that caspase 2 functions as an upstream negative regulator of NFkB in a pathway that requires at least one NFkB site in the proximal survivin promoter. Consistent with this model, active caspase 2 abolished NFkB reporter activity in tumor necrosis factor-a (TNFa)-stimulated HCT116 cells, whereas catalytically dead caspase 2 had no effect (Figure 8d ).
Caspase 2 cleavage of RIP1
We next searched for upstream activator(s) of NFkB that may be potentially cleaved by caspase 2, and we focused on RIP1 (Festjens et al., 2007) for its role in TNFa-induced (Micheau and Tschopp, 2003) and DNA damage-induced (Janssens et al., 2005) NFkB activation. Unconjugated or bead-conjugated recombinant caspase 2 cleaved 35 S-labeled recombinant RIP1 in vitro, with appearance of proteolytic fragments of approximate molecular weights of 56 and 20 kDa, respectively (Figure 9a ). Addition of the caspase 2 inhibitor, z-VDVAD-fmk prevented RIP1 cleavage by caspase 2 (Figure 9a ). In addition, caspase 2 cleaved a 35 S-labeled -COOH terminus RIP1 fragment comprising of residues 351-672, whereas a RIP1 NH 2 fragment comprising of residues 1-350 was not affected (Figure 9b ). Consistent with these data, transfection of constitutively active caspase 2 in HCT116 cells decreased the expression of endogenous full-length RIP1 and reduced the levels of Bcl-x L , another NFkB target gene (Figure 9d ). In contrast, XIAP levels were not affected ( Figure 9c ) and transfection of catalytically dead caspase 2 did not modulate RIP1 expression ( Figure 9c ).
Consistent with a role of RIP1 in NFkB regulation of survivin, siRNA silencing of RIP1 in TNFa-stimulated HCT116 cells resulted in decreased expression of endogenous survivin (Figure 9e) . Similarly, transfection of HCT116 cells with a p65 subunit of NFkB (p65-NFkB) increased endogenous survivin (Figure 9f) , whereas a S529A p65-NFkB dominant negative mutant (Wang and Baldwin Jr, 1998 ) caused loss of survivin expression ( Figure 9f ). Finally, siRNA silencing of RIP1 in HCT116 cells inhibited the induction of survivin mediated by TNFa (Figure 9g ) in a response reversed by transfection of WT but not S529A mutant p65-NFkB (Figure 9g ).
Discussion
In this study, we have shown that caspase 2, an apical caspase with still largely elusive functions (Krumschnabel et al., 2009) , actively represses survivin gene transcription in tumor cells. In turn, acute loss of survivin causes mitotic defects, increased sensitivity to apoptosis and complete loss of tumorigenicity in vivo. Mechanistically, this pathway involves caspase 2 cleavage of the NFkB activator, RIP1 (Festjens et al., 2007) , which shuts off transcription of NFkB-responsive antiapoptotic genes, including survivin (Kawakami et al., 2005) .
Apart from a well-characterized mechanism of caspase 2 activation in response to DNA damage (Tinel and Tschopp, 2004) , other pathophysiological activation platform(s) for this caspase have been far less clear (Krumschnabel et al., 2009) . Here, conventional (CDDP or taxol) or molecularly targeted (17-AAG) anticancer agents produced concentration-and timedependent caspase 2 activity in tumor cells, in agreement with the effect of other chemotherapeutic agents (Mhaidat et al., 2007) or stress response modifiers (Yeung et al., 2006) . Caspase 2 activation under these conditions was not uniformly preceded by generation of caspase 3 activity, which activates caspase 2 by removing its prodomain (Van de Craen et al., 1999) , suggesting that at least certain anticancer regimens may activate caspase 2 upstream of effector caspase(s) (Yeung et al., 2006) .
Recent evidence suggests that survivin functions as a 'nodal' IAP protein (Srinivasula and Ashwell, 2008) , orchestrating cell division mechanisms, cytoprotection and modulation of the cellular stress response, especially in cancer (Altieri, 2008) . In this context, a role of caspase 2 as a novel repressor of the survivin gene adds to the multiple pathways that fine-tune survivin expression in tumor cells, including transcriptional (Altieri, 2008) , translational (Vaira et al., 2007) and posttranslational (O' Connor et al., 2000; Wheatley et al., 2007) modifications. Similar to the phenotype induced by blocking transcriptional activators of survivin, for instance Wnt/b catenin (You et al., 2004) , Stat3 (Zhou et al., 2009) or Notch (Lee et al., 2008) , heightened caspase 2 activity resulted in loss of endogenous survivin, causing mitotic defects, reduced cell proliferation and sensitization to apoptotic stimuli (Altieri, 2008) . Functionally, this resulted in complete loss of tumorigenicity in vivo, a phenotype that mirrors the effect of genetic deletion of caspase 2 of delayed apoptosis (Ho et al., 2008) , increased cell proliferation, enhanced cellular transformation and accelerated tumor growth in vivo (Ho et al., 2009 ). Similar to the data observed here, a recent study implicates a role for nuclear caspase 2 in the maintenance of a G2/M checkpoint in response to DNA damage (Shi et al., 2009) . Although these results collectively suggest a role of caspase 2 in cell cycle progression, more work is needed to ascertain whether changes in survivin levels also contribute to this pathway. Taken together, these data support a model of caspase 2 as a novel tumor suppressor in vivo, and identify acute survivin gene silencing as one of the pivotal effectors of this response.
Although the overexpression of survivin seen in most human cancers likely reflects activation of multiple oncogenic pathways (Altieri, 2008) , complementary pathways have also been identified that keep survivin levels low in normal cells. Accordingly, tumor suppressors, including p53 (Hoffman et al., 2002; Mirza et al., 2002) , Rb (Jiang et al., 2004) , BRCA1 (Wang et al., 2008) or PTEN (Guha et al., 2009) , have all been shown, similar to caspase 2 (this study), to acutely silence the survivin gene by different mechanisms. Whether this pathway is responsible for the low to undetectable levels of survivin observed in most normal adult tissues (Altieri, 2008) remains to be elucidated. However, it is possible that transcriptional silencing of survivin by various effectors may provide a mandatory requirement for efficient tumor suppression (Lowe et al., 2004) , whereas unrestrained survivin gene expression may constitute an obligatory step in the establishment of the transformed clone(s).
The mechanistic underpinning of how caspase 2 antagonizes tumor growth was not elucidated in a recent study (Ho et al., 2009) . Here, we show that this pathway involves inhibition of NFkB signaling by direct cleavage of its upstream activator, RIP1 (Festjens et al., 2007) . Consistent with this model, the catalytic activity of caspase 2 was required for survivin gene silencing, and differential expression of RIP1 or NFkB was sufficient to modulate endogenous survivin levels in tumor cells. This is in agreement with other data of NFkB induction of survivin gene expression (Kawakami et al., 2005) 2008) and the preliminary identification reported here of at least one functional NFkB-responsive site in the proximal survivin promoter. Clearly, other pathways for NFkB activation could participate in modulating survivin gene expression using potential additional NFkB sites in the survivin promoter. In this context, RIP1 functions as an ubiquitin-regulated component of a TNFa-induced multimolecular protein complex that participates in cell survival through NFkB and mitogenactivated protein kinase signaling (Festjens et al., 2007) .
Although a non-catalytic mechanism of caspase 2mediated NFkB activation has been proposed (Lamkanfi et al., 2005) , our findings are at variance with this model (Lamkanfi et al., 2005) and suggest that caspase 2 functions as a pro-apoptotic effector antagonizing NFkB-mediated cell survival (Tinel et al., 2007) . There is precedent for a role of caspase(s) executing a similar response through RIP1 cleavage, such as caspase 8 proteolysis of RIP1 at Asp324 has been implicated in suppression of NFkB-dependent survival in tumor cells (Lin et al., 1999) and regulation of macrophage differentiation (Rebe et al., 2007) . Caspase 2 cleavage of RIP1 was not observed in an earlier study (Lamkanfi et al., 2005) . However, we showed here that this response was largely reversed by a caspase 2 inhibitor, z-VDVAD-fmk (Krumschnabel et al., 2009) , and involved a -COOH terminus fragment of RIP1 comprising of residues 351-672. Although several Asp residues are present in this region as candidate cleavage site(s), none conforms to a canonical VDVAD sequence, in agreement with the promiscuous substrate recognition of caspase 2.
In summary, we have found that caspase 2 functions in a broad tumor suppression network, lowering a general antiapoptotic threshold via interruption of NFkB signaling (Karin, 2006) and acute silencing of survivin gene expression (Altieri, 2008) . Among the portfolio of apoptosis modifiers, strategies to restore caspase activity in tumors are being pursued for therapeutic opportunities (Fesik, 2005) . On the basis of the data presented here, restoring caspase 2 activity may be beneficial in tumors with elevated NFkB activity and high levels of survivin, thus potentially 'addicted' to this general cytoprotective pathway (Karin, 2006) .
Materials and methods
Cells and culture conditions
Human colorectal p53 þ / þ and p53 À/À HCT116 cancer cells were kindly provided by Dr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA). For generation of stable clones, HCT116 p53 þ / þ cells or lung cancer H460 cells were transfected with WT hemagglutinin (HA)-tagged caspase 2 or caspase 9 cDNA, and selected in 1 mg/ml G418 (Gibco, Carlsbad, CA, USA). Colonies were picked after 2 weeks and confirmed for expression of HA or caspase 9 by western blotting. Breast adenocarcinoma MCF-7 cells stably transfected with survivin were described previously (Ghosh et al., 2008) . 
Plasmids and antibodies
A full-length WT caspase 2 cDNA (Invitrogen, Carlsbad, CA, USA) was amplified by PCR with primers 5 0 -ATATACTC GAGTAAGCGGGAAATGGCGGCGCCG-3 0 (forward) and 5 0 -ATAGAGTCTAGATCATGTGGGAGGGTGTCCTGG-3 0 (reverse), digested with XbaI and XhoI and inserted in HAtagged pcDNA3.1. For recombinant protein expression, a fulllength caspase 2 cDNA was cloned into pGEX-4T vector (Amersham Biosciences, Piscataway, NJ, USA) using SmaI and XhoI restriction sites. Primers used for amplification of recombinant caspase 2 (C2) were 5 0 -ATATACCCGGGTAAG CGGGAAATGGCGGCGCCG-3 0 (forward) and 5 0 -ATAGA GCTCGAGTCATGTGGGAGGGTGTCCTGG-3 0 (reverse). A constitutively active caspase 2 cDNA (Casp. 2 152 Ac) was generated by PCR by removal of the prodomain to mimic the processed caspase using primers 5 0 -GCCTGTCGACAGA TACTGTGGAACACTCC-3 0 (forward) and 5 0 -ATAGAGCT CGAGTCATGTGGGAGGGTGTCCTGG-3 0 (reverse). Fulllength or truncated caspase 2 mutants were generated by replacing the active site Cys320 to Ala (C320A) using site-directed mutagenesis (Stratagene, Cedar Creek, TX, USA). The catalytic activity of various caspase 2 constructs was determined using a colorimetric assay kit (Calbiochem, La Jolla, CA, USA) in the presence of VDVAD-pNA as a substrate.
An 830 nt mouse survivin promoter construct fused upstream of GFP (ms-830-GFP) was characterized previously (Xia and Altieri, 2006) . A putative NFkB consensus site at position À150 nt in ms-830-GFP was mutated using forward primer 5 0 -GGCGTGGGGCctGACTaTCCCGGCTCG-3 0 with the mutated site indicated in bold (NFkBD). A RIP1 cDNA was the gift of Dr Michelle Kelliher (University of Massachusetts Medical School, Worcester, MA, USA). WT or mutant (S529A) p65 NFkB cDNA was the gift of Dr Neil Silverman (University of Massachusetts Medical School). A truncated RIP1 NH 2 fragment (residues 1-350) was generated using primers 5 0 -GGATCCCCGGAATTCAGAATGCAACCAGA CATG-3 0 (forward) and 5 0 -TTACTCCTCGAGAGGACCC TACCCAAGTCCCTG-3 0 (reverse). A RIP1 -COOH terminus fragment (residues 351-672) was generated using primers 5 0 -TCCCAGGAATTCGGGATGGGTCCTGTGGAGGAG-3 0 (forward) and 5 0 -CGGCCGCTCGAGTTAGTTCTGGCT GACGTAAAT-3 0 (reverse). Both RIP1 fragments were amplified and digested with EcoR1 and XhoI and inserted into pcDNA3.1 vector. The antibodies against caspase 2, 3, 8 and 9 were from Cell Signaling (Danvers, MA, USA). Antibodies to the p65 subunit of NFkB, Bcl-x L (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), survivin (Novus Biologicals, Littleton, CO, USA) or RIP1 (BD Biosciences, San Jose, CA, USA) were used.
Protein and RNA analysis Recombinant caspase 2 fused to GST was expressed in BL-21 Escherichia coli strain, as described (Kang and Altieri, 2006) . All RIP1 cDNA constructs (full length, NH 2 terminus and -COOH terminus fragments) were transcribed and translated in vitro using T7, TNT-coupled rabbit reticulocyte lysate system (Promega, Madison, WI, USA). Aliquots of 35 Smethionine-labeled RIP1 were incubated with recombinant caspase 2 at 37 1C for 1 h, separated by sodium dodecyl sulfate gel electrophoresis and analyzed by autoradiography. Changes in survivin mRNA expression were analyzed by semi-quantitative reverse transcription-PCR using primers for survivin, 5 0 -GCATGGGTGCCCCGACGTTG-3 0 (forward) and 5 0 -GCT CCGGCCAGAGGCCTCAA-3 0 (reverse), and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described (Xia and Altieri, 2006) or by quantitative real-time PCR, using fluorescent TaqMan and the gene expression assays Hs00153353_m1BIRC5 (survivin) and Hs9999905_m1GAPDH from Applied Biosystem (Foster City, CA, USA). Total RNA was extracted using RNeasy (Qiagen, Valencia, CA, USA) and reverse transcribed using first strand cDNA synthesis kit (Invitrogen). Analysis of gene expression was done using a relative quantification ddCt method.
Transfections and reporter assays b-Galactosidase-normalized survivin promoter (pLuc-1430c, pLuc-649c, pLuc-441c and pLuc-230c) luciferase activity was quantified as described (Li and Altieri, 1999) . Differential ms-830-GFP expression in transfected cells was analyzed by fluorescence microscopy and western blotting, as described (Xia and Altieri, 2006) . Gene silencing experiments by siRNA directed to caspase 2, 3, 8 or RIP1 (Dharmacon, Lafayette, CO, USA) were carried out as described (Lee et al., 2008) . Two independent siRNA oligonucleotides targeting caspase 2 were tested to eliminate the possibility of off-target effects (data not shown). A non-targeted siRNA characterized previously (Lee et al., 2008) was used as control.
Flow cytometry
Transfected HCT116 cells were treated with the apoptotic stimulus, STS (0.8-1 mM), and analyzed by multiparametric flow cytometry using CaspaTag caspase 3 activity kit (Millipore, Billerica, MA, USA). In some experiments, transfected cells were treated with STS and analyzed for nuclear morphology of apoptosis after 14-16 h by fluorescence microscopy. Cell cycle analysis was carried out in thymidine-synchronized HCT116 stable transfectants. Cells were treated with 1 mM thymidine for 16 h to induce a G1-phase cell cycle arrest followed by release and collection of cells at various time points. Analysis of DNA content was done by propidium iodide staining and flow cytometry.
Electrophoretic mobility shift assay
Nuclear fractions were purified from HCT116 cells using NucBuster kit (Novagen, San Diego, CA, USA). DNA probes were synthesized using the survivin promoter sequence containing the NFkB site in bold (5 0 -GTGGGGC GGGACTTTCCCGGCTC-3 0 ) and end-labeled with [g-32 P]deoxyadenosine triphosphate, 1 ml T4 kinase and 2.5 ml PNK for 15 min at 37 1C and then for 15 min at 65 1C. The labeled probes were purified using nucleic acid purification columns (Bio-Rad, Hercules, CA, USA) and incubated with 15 mg of nuclear extract, as described (Lee et al., 2008) . To determine the binding specificity, 100-fold excess of unlabeled competitor, mutant competitor or antibody to p65 subunit of NFkB (Santa Cruz) was used as indicated. The reactions were resolved on a 5% non-denaturing polyacrylamide gel and visualized by autoradiography.
Analysis of tumorigenicity
Stably transfected HCT116 cells were cultured in soft agar for 14 days at 37 1C and colonies (>50 cells) were counted by light microscopy. All experiments involving animals were approved by an Institutional Animal Care and Use Committee at the University of Massachusetts Medical School. HCT116 transfectants were injected (2 Â 10 6 in 100 ml of phosphate-buffered saline) subcutaneously into the flanks of 6-8-weeks old female CB17 SCID/beige mice (three mice per group, two tumors per mouse, two independent experiments). Tumor growth was monitored every other day and tumor size was calculated with a caliper according to the formula L Â W 2 /2 (mm 3 ).
Statistical analysis
Data were analyzed using the unpaired t-test on a GraphPad software package for Windows (Prism 4.0). A P-value of 0.05 was considered as statistically significant.
